Relay Therapeutics (RLAY) Current Assets (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Current Assets data on file, last reported at $658.5 million in Q1 2026.

• Current Assets for Q1 2026 came in at $658.5 million, down 10.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $658.5 million (down 10.98% YoY), and the FY2025 annual result was $578.3 million, down 28.54% from the prior year.
• Current Assets improved to $658.5 million in Q1 2026 per RLAY's latest filing, from $578.3 million in the prior quarter.
• Over five years, Current Assets peaked at $1.1 billion in Q3 2022 and troughed at $578.3 million in Q4 2025.
• A 5-year average of $809.0 million and a median of $809.2 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 70.09% in 2022, then dropped 28.54% in 2025.
• A 5-year view of Current Assets shows it stood at $1.0 billion in 2022, then dropped by 24.46% to $770.1 million in 2023, then increased by 5.08% to $809.2 million in 2024, then retreated by 28.54% to $578.3 million in 2025, then increased by 13.87% to $658.5 million in 2026.
• Business Quant data shows RLAY's Current Assets at $658.5 million in Q1 2026, $578.3 million in Q4 2025, and $624.0 million in Q3 2025.